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Abstract
Background—Circulating levels of acute phase reactant proteins such as plasma C-reactive protein
(CRP) are likely influenced by multiple genes regulating the innate immune response.
Methods—We screened a set of 16 inflammation-related genes for association with CRP in a large,
population-based study of healthy young adults (n=1,627). Results were validated in two independent
studies (n=1,208 and n=4,310), including a pooled analysis of all 3 studies.
Results—In the pooled analysis, the minor allele of IL1RN 1018 (rs4251961) within the gene
encoding interleukin-1 receptor antagonist (IL-1RA) was significantly associated with higher mean
plasma log(CRP) level (p < 1 × 10−4). The same IL1RN 1018 allele was associated with higher mean
plasma log(IL-6) levels (p=0.004). In the pooled analysis, the minor allele of IL1RN 13888
(rs2232354) was associated with higher fibrinogen, (p = 0.001). The IL1RN 1018 and 13888 variant
alleles tag a clade of IL1RN haplotypes linked to allele 1 of a 86 bp VNTR polymorphism. We
confirmed that the IL1RN 1018 variant (rs4251961) was associated with decreased cellular IL-1RA
production ex vivo.
Conclusions—Common functional polymorphisms of the IL1RN gene are associated with several
markers of systemic inflammation.
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INTRODUCTION
C-reactive protein (CRP) is a systemic marker of inflammation in humans [1]. Basal plasma
CRP levels correlate with age, sex, ethnicity, smoking and body mass index (BMI). High basal
levels of CRP predict future cardiovascular disease (CVD) events in otherwise healthy adults
[2]. CRP, fibrinogen, and other acute phase proteins are produced primarily in the liver. CRP
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biosynthesis is largely under transcriptional control of interleukin (IL)-6, but other cytokines
such as IL-1β and tumor necrosis factor (TNF)-α also contribute [3,4]. IL-6 and IL-1 activate
the transcription factors STAT3, C/EBP, and the NF-κB/Rel family, which interact
synergistically to induce maximal CRP gene transcription [5].
Recently, several polymorphisms of the CRP gene were associated with plasma CRP
concentration [6,7], but these account for only a small proportion of the reported overall 35–
50% heritability [8–11]. The remaining genetic determinants of CRP level are largely
unknown. We hypothesized that gene variants in pathways related to cytokine signaling and
the acute phase response influence CRP levels. We tested this by using a single nucleotide
polymorphism (SNP) tagging approach to assess common genetic variation within a set of 16
candidate genes in young, healthy adults from the population-based Coronary Artery Risk
Development in Young Adults (CARDIA) study. We validated our initial CARDIA findings
of association between IL1RN genotypes and plasma CRP in two additional population studies
of older adults, and also tested for association with other pro-inflammatory biomarkers
(fibrinogen and interleukin-6). Finally, we assessed the functional influence of the associated
IL1RN polymorphisms on cellular IL-1RA production.
METHODS
Initial screening of candidate gene SNPs and plasma CRP levels was performed in younger
European-American men and women from the community-based CARDIA study. Subsequent
replication of genetic association findings with inflammation biomarkers was performed within
2 studies of older adults, the Carotid Lesion Epidemiology and Risk (CLEAR) study and the
Cardiovascular Health Study (CHS). In all studies, participants provided written informed
consent.
CARDIA study participants and candidate gene genotyping
The Coronary Artery Risk Development in Young Adults (CARDIA) Study is a prospective
cohort study of the development of cardiovascular risk factors in young adults. Beginning in
1985, 5,115 participants aged 18–30 years were recruited from four clinical sites located in
Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California.
Based on our hypothesis that common SNPs within candidate genes involved in cytokine
signaling and acute phase response are associated with plasma CRP levels, we typed 121
tagSNPs across 16 genes to screen for association in CARDIA (Supplemental Table I), as
described under Supplemental Methods (please see http://atvb.ahajournals.org.). For the
current study, we included a subset of n=1,627 European-American participants who had
genotyping performed and had CRP and fibrinogen concentration measured at the year 7 and
year 5 exams, respectively.
CLEAR Study
The Carotid Lesion Epidemiology and Risk (CLEAR) study is a Seattle-based case-control
study of severe carotid artery disease (CAAD). Study participants were recruited from the
University of Washington, Virginia Mason Medical Center, and Veterans Affairs Puget Sound
Health Care System. The study subjects in the current analysis are European-American men
ranging in age from 37 to 89 years, including 499 CAAD cases, 646 controls, and 63 individuals
with intermediate internal carotid stenosis levels (see Supplemental Methods). Five of seven
IL1RN tag SNPs were successfully typed in CLEAR: 1018 (rs4251961), 10257 (rs4252001),
13888 (rs2232354), 15132 (rs432014), and 15453 (rs380092), with numbering based on
GenBank accession number AY196903 (Supplemental Figure I).
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The Cardiovascular Health Study (CHS) is a prospective population-based cohort study of
5,888 men and women aged 65 and older recruited from four U.S. field centers: Forsyth County,
North Carolina; Sacramento County, California; Washington County, Maryland; and
Pittsburgh, Pennsylvania. At study entry, CHS participants underwent assessment of CVD risk
factors and measurement of plasma biomarkers, including CRP, fibrinogen, and interleukin-6,
as described under Supplemental Methods. The final sample for the current study included
4,310 European-American men and women who consented to DNA testing. In CHS, all 7
IL1RN tagSNPs were typed as in CARDIA: 1018 (rs4251961), 2765 (rs315919), 5848
(rs3213448), 10257 (rs4252001), 13888 (rs2232354), 15132 (rs432014), and 15453
(rs380092) (Supplemental Figure I).
Statistical analysis
Allelic correlation as a measure of linkage disequilibrium (LD) between pairs of polymorphic
sites was calculated as r2. Haplotypes across the IL1RN gene were inferred from the unphased
tagSNP genotype data using the haplotype reconstruction algorithm, fastPHASE [12].
Associations between SNP genotypes and quantitative CRP, fibrinogen, or IL-6 levels were
assessed using multiple linear regression. CRP and IL-6 were log-transformed to reduce
skewness. Linear regression models were adjusted for age, gender, field center, BMI, smoking
status (and CAAD status in the CLEAR study). Covariate-adjusted SNP-specific change in
estimated mean plasma biomarker level was estimated from the regression coefficients (β),
separately for heterozygote and rare homozygote genotypes, using the homozygous wild type
for each genotype as the reference group. The results obtained for unadjusted models were
nearly identical to the covariate-adjusted results (data not shown). To account for multiple
tagSNPs and genes tested in CARDIA, p-values were determined empirically by permutation
testing. In addition, we performed permutation tests that provide a global test of significance
across all the SNPs each gene, corrected for the number of genes tested. Both the individual
SNP and candidate gene experiment-wise significance permutation tests take into account the
correlation among tests of SNPs in LD [13]. Candidate gene testing was carried forward from
stage 1 in CARDIA to stage 2 in the CLEAR and CHS replication studies if any of the individual
SNP p-values were nominally <0.02.
Pooled analysis of CARDIA, CLEAR, and CHS genotype and phenotype data
Summary effect estimates for change in log(CRP) or fibrinogen associated with each additional
copy of the minor SNP allele were calculated by including age, gender, and smoking status,
BMI, and disease status as covariates using a random-effects meta-analysis model with inverse-
variance weighting [14]. Heterogeneity of results between studies was assessed with Q
statistics, which test for statistically significant differences among the pooled strata estimates.
Statistical analyses were carried out by using the STATA software package v.8.2 (Stata
Corporation, College Station, Texas).
As an additional method of combining data across studies, we used the Bayesian imputation
and regression analysis program of Servin and Stephens [15] implemented in BIMBAM
(http://stephenslab.uchicago.edu/software.html) to quantify the strength of evidence for
association by computing Bayes Factors (BFs) for each ‘typed’ and ‘untyped’ polymorphism
in IL1RN. Using this approach, patterns of correlation or LD among the markers typed in each
phenotypic data set (CARDIA, CLEAR, and CHS) and the more densely-genotyped
SeattleSNPs re-sequencing panel were used to impute the genotypes at all IL1RN markers in
all individuals, allowing the combined data to be used when assessing the strength of the
association between genotypes and the phenotype [15].
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Analysis of IL1RN genotype, ILRN gene expression, and whole blood IL1-RA levels
Healthy, non-smoking individuals between the ages of 18–65 years of age were recruited from
the metropolitan Seattle area (n=285). Fasting blood samples were incubated ex vivo with the
innate immune stimulus peptidoglycan or with media alone. IL1RN mRNA and IL1-RA protein
levels were measured, as described in detail under Supplemental Methods.
RESULTS
Study participant characteristics
Descriptive characteristics of participants for all 3 population-based studies are shown in Table
1. At the year 7 CARDIA exam, the mean age of the CARDIA study subjects was 33 years,
and 53% were women. The CLEAR study participants had a mean age of 67, and 15% were
women. The mean age of the CHS participants at study entry was 73 years, and 57% were
women. As expected, there was a greater prevalence of CVD risk factors and prevalent CVD
among the older CHS and CLEAR participants than among the younger CARDIA cohort.
Association between IL1RN variants and CRP phenotype in CARDIA
We screened 121 common SNPs across 16 candidate inflammation genes in 1,627 CARDIA
individuals for association with plasma CRP levels. Genotype, allele frequencies, and HWE
p-values are shown in Supplemental Table I. Supplemental Table II shows the results for global
tests of association for each candidate gene, and Supplemental Table III shows the results of
tests of association for each individual SNP. When tested at the level of the candidate gene,
the global permutation test for association of IL1RN with plasma CRP levels, corrected for
multiple testing, was statistically significant (p=0.01). IL1RN 13888 (rs2232354) (minor allele
frequency 20%), was significantly associated with plasma CRP level (p = 3 × 10−4; experiment-
wise corrected p=0.04). When adjusted for age, gender, field center, BMI, and smoking status,
each additional copy of the IL1RN 13888 (rs2232354) minor allele was associated with 1.19
(1.08 – 1.30) mg/L higher mean CRP level (Table 2), explaining <1% of the variance. One
other SNP, TNF 4101 (rs1800628), had a nominal p-value below 0.02 (Supplemental Table
III).
Linkage disequilibrium and haplotype structure of the IL1RN gene
The evolutionary haplotype structure of the IL1RN gene derived from SeattleSNPs genomic
re-sequencing data (Supplemental Figure I) is shown in Supplemental Figure II. Seven
IL1RN tagSNPs defined 4 major haplo-groups or clades in the European-American population.
Clade A is tagged by IL1RN 1018 (rs4251961), and 13888 (rs2232354). The correlation
coefficient (r2) between the minor alleles of IL1RN 1018 and 13888 was 0.4. In intron 3 of
IL1RN, there is a well-known 86-bp variable number of tandem repeat (VNTR) polymorphism
[16], which consists of two common variants containing either 4 copies (allele 1) or 2 copies
(allele 2). In the SeattleSNPs re-sequencing data, clades A, B, and C were associated with allele
1 of the IL1RN VNTR polymorphism. Clade D, tagged by the minor allele of IL1RN 15132
(rs432014) was in complete LD with allele 2 of the VNTR (r2 = 0.99).
Meta-analysis of IL1RN genotype – CRP and other inflammation phenotype associations
The minor allele of IL1RN 13888 (rs2232354) was associated with increased plasma CRP
levels in CLEAR (p-value = 0.004), confirming the association observed in CARDIA (Table
2). In CHS, the minor allele of the other clade A-tagging SNP, IL1RN 1018 (rs4251961), was
associated with higher CRP levels (Table 2). In a pooled, meta-analysis of all 3 studies (Table
2), IL1RN 1018 (rs4251961) had the strongest evidence for association with CRP phenotype
(p < 1 × 10−4; p for heterogeneity = 0.95). There was weaker evidence that IL1RN 13888
(rs2232354) was associated with higher CRP (p =0.06; p for heterogeneity = 0.01), and that
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IL1RN 15132 or rs432014 (p =0.06; p for heterogeneity = 0.46) and 15453 or rs380092 (p
=0.008; p for heterogeneity = 0.54) were associated with lower CRP. None of the IL1RN
genotype-CRP phenotype associations changed upon additional adjustment for CRP tagSNPs
(data not shown).There was no association between TNF 4101 (rs1800628) and CRP in the
pooled analysis (p=0.44).
Bayesian imputation and regression analysis of all 156 typed and untyped IL1RN
polymorphisms (including the 86-bp VNTR) confirmed that IL1RN 1018 (rs4251961) and an
untyped SNP in strong LD, IL1RN 19327 (rs315919) had the strongest evidence for association
with CRP [log10(Bayes Factors) = 2.2 and 2.0, respectively; permutation p-values = 0.001],
followed by IL1RN 13888 or rs22323540 [log10(Bayes Factor)=1.5; permutation p-
value=0.003]. Allele 2 of the VNTR polymorphism showed much weaker evidence of
association with CRP [log10(Bayes Factor)=0.3; permutation p-value = 0.04].
In pooled analysis of fibrinogen phenotype, the minor allele of IL1RN 13888 (rs2232354) was
associated with 4.11 (95% CI 1.60 – 6.57; p=0.001) mg/dL higher fibrinogen, (p for
heterogeneity = 0.55). In CHS, the minor allele of IL1RN 1018 (rs4251961) was associated
with 0.04 ± 0.01 higher mean plasma log(IL-6) levels (p=0.004), while the minor allele of
IL1RN 2765 was associated with 0.03 ± 0.01 lower log(IL-6) levels (p=0.02).
IL-1RA production in whole blood ex vivo is associated with IL1RN genotype
There was an association between the clade A IL1RN 1018 (rs4251961) C allele and lower
IL-1RA production (normalized for neutrophil count) in response to the innate immune
stimulus peptidoglycan (p = 4.5 × 10−6; Table 3). There was also an association between
normalized IL-1RA production in response to peptidoglycan and the clade D 15132 (rs432014)
genotype; the minor C allele was associated with higher IL-1RA levels (Table 3). There was
no association between IL1RN genotype and IL-1RA production in blood stimulated with
media alone (not shown). In a subgroup of 57 subjects selected to represent equal numbers of
each IL1RN 1018 (rs4251961), genotype group, there was a non-significant trend (p=0.2)
towards higher levels of neutrophil-normalized IL1RN transcript with increasing copies of
IL1RN 1018T (Supplemental Figure III).
DISCUSSION
Using data from 3 large studies, we demonstrate that common variants of the IL-1RA gene
(IL1RN) are associated with multiple systemic inflammation phenotypes. The minor alleles of
IL1RN 1018 (rs4251961) and 13888 (rs2232354), tagging haplotype clade A, were associated
with higher circulating levels of CRP, fibrinogen, and IL-6 levels. The same clade A alleles
were associated with reduced cellular IL-1RA production ex vivo in response to an
inflammatory stimulus.
Our results are supported by several family-based linkage and association studies involving
the IL1RN gene region in CVD patients. In a recent genome-wide linkage analysis, the region
on chromosome 2 containing IL1RN was identified as influencing CRP levels in European
families with early-onset coronary heart disease (CHD) [17]. In smaller, hospital-based studies
of CHD patients, allele 2 of the 86 bp IL1RN VNTR polymorphism was associated with lower
plasma CRP and fibrinogen concentration [18,19]. Our findings extend the importance of
IL1RN genotype as a determinant of CRP and fibrinogen levels among the general population
of younger and older European American adults. By performing a pooled meta-analysis and
imputation analysis to combine genotype and phenotype data across studies, and also to test
untyped SNPs identified through a genomic re-sequencing panel, we demonstrated that
IL1RN 1018 (rs4251961) had the strongest evidence for association with CRP.
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In separate ex vivo whole blood analyses, we were able to demonstrate that the amount of IL1-
RA produced by leukocytes in response to an inflammatory stimulus is influenced by IL1RN
genotype. While circulating IL1-RA levels were not measured in our 3 population studies, our
cellular IL1-RA results are consistent with a recent report from the Invecchiare in Chianti study
[20]. Rafiq et al [20] found the IL1RN 1018 (rs4251961), variant (clade A) was strongly
associated with lower circulating IL-1RA levels, while another SNP in strong linkage
disequilibrium with the VNTR allele 2 haplotype (clade D) was associated with higher soluble
IL-1RA levels. Interestingly, Rafiq et al [20] also reported that the IL1RN 1018-containing
haplotype was associated with increased circulating levels of other inflammatory mediators
such as interferon-γ, IL-1β, adiponectin, and α2 macroglobulin, another hepatic acute phase
protein. Together with our results, these findings further support the role of common IL1RN
polymorphisms on circulating levels of multiple biomarkers of systemic inflammation
CRP, fibrinogen, and IL-6 are plasma proteins primarily synthesized in the liver as part of the
acute phase response to inflammatory stimuli. The observed IL1RN genotype associations are
consistent with the known biologic role of IL-1RA, which inhibits overall IL-1 related innate
immune responses [21]. IL1-RA is produced in high amounts by peripheral blood neutrophils
stimulated with innate immune agonists [22,23]. The soluble form of IL-1RA is also produced
by hepatocytes and is itself regulated by pro-inflammatory cytokines and NF-κB and C/EBP,
with circulating IL-1RA levels rising during various inflammatory conditions and tissue injury
[24]. Therefore the direction of observed IL1RN genotype – inflammatory phenotype
associations are consistent with known biology of IL-1RA in inflammation: the minor alleles
of IL1RN 1018 (rs4251961), and 13888 (rs2232354) are associated with lower IL1-RA
production and thus higher inflammation biomarker levels.
Strengths of the current study include the use of 3 large, independent samples to demonstrate
replication of IL1RN genotype – CRP association, assessment of additional inflammation-
related phenotypes, including ex vivo cellular IL-1RA production, and the use of meta-analysis
methods to combine genotype and phenotype data across studies and to impute untyped SNPs.
While the IL1RN 1018 variant was strongly associated with cellular IL-1RA production, the
precise molecular functional sites remain to be identified. IL1RN 1018 (rs4251961) is located
3 bp upstream of a predicted YY1 transcription factor binding site within a region of the
intracellular IL-1RA promoter that appears to regulate LPS-induced expression in
macrophages [25]. In our Bayesian imputation and regression analysis, IL1RN 19327
(rs315919), which is located in the 3’ flanking region and is in strong LD with IL1RN 1018
(r2=0.8), showed nearly as strong a signal of association with CRP. Examination of
polymorphism data from the HapMap shows that aIL1RN 1018 (rs4251961) is also in strong
linkage disequilibrium with 8 other SNPs located in the 3’ untranslated and flanking region of
IL1RN that form an extended IL1RN haplotype. Therefore, additional polymorphic sites located
either intrinsic or extrinsic to IL1RN may affect athe function of either the secreted or
intracellular IL-1RA promoter regions.
In summary, we have identified several common variants of the IL1RN gene associated with
circulating levels of multiple inflammatory biomarkers in European American adults. IL-1RA
has beneficial effects in many disease models, and recombinant human IL-1RA is currently
approved or under investigation for treatment of diseases such as stroke, diabetes, and arthritis
[26–28]. Therefore, the current findings have potential implications for primary risk
stratification and targeted drug therapy [29] in a wide range of CVD, metabolic, and other
inflammation-related disorders.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Descriptive characteristics of participants from CARDIA, CLEAR, and CHS
Characteristic CARDIA CLEAR CHS
Number 1,627 1,208 4,310
Mean age, years [range] 33 [24 – 39] 67 [31 –92] 73 [65 – 98]
Female sex 1023 (53) 186 (15) 2580 (57)
Current smokers 378 (21) 203 (17) 497 (11)
Body mass index (kg/m2) 25.5 ± 5.1 28.3 ± 5.2 26.4 ± 4.5
Total cholesterol (mg/dL) 178 ± 35 192 ± 39 212 ± 39
LDL cholesterol (mg/dL) 108 ± 31 112 ± 32 130 ± 36
HDL cholesterol (mg/dL) 51 ± 14 49 ± 16 54 ± 16
Triglycerides (mg/dL) 94 ± 86 148 ± 150 144 ± 79
Diagnosis of hypertension 54 (3) 703 (58) 2530 (56)
Diabetes 22 (1) 195 (16) 657(15)
Data are presented as number (%) or mean ± standard deviation, unless otherwise indicated.
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